ICLR

ICON Public Limited Company

ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON employed approximately 15,730 employees in 93 locations in 41 countries as at December 31, 2020.

ICON Public Limited Company (ICLR) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Value (C-). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C-
Factor Score 1.9 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
B+
Factor Score 3.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 79.9
EV / EBITDA 36.3
Rev Growth YoY -2.9%
Gross Margin 23.4%
Price Return 3M 19.2%
Price Return 12M 26.6%
Catalyst Signal 0.00
Market Cap $15.0B
TTM Revenue $8.2B
Price / Sales 1.8
ROE 4.7%

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C- (1.9) C- (2.0) C+ (2.7) B+ (3.8) C+ (2.6) C+ (2.6)
2026-11-05 D+ (1.8) C- (2.0) C+ (2.7) B+ (3.7) C+ (2.7) C+ (2.6)
2026-10-29 C- (1.9) D+ (1.7) C+ (2.7) B+ (3.7) C+ (2.7) C+ (2.5)
2026-10-22 D+ (1.6) D+ (1.7) C+ (2.7) B (3.3) C+ (2.6) C (2.4)
2026-10-15 D+ (1.7) D+ (1.7) C+ (2.7) B (3.3) C+ (2.6) C (2.4)
Page 1 of 4